Phase 3 N=1,800 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
Covid19
Primary: Time to Sustained Recovery in Days — 12; 13 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=29 Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
End Stage Renal Disease · Rejection of Renal Transplant
Primary: Change in Kidney Transplant Function From 2 Weeks Post Transplant Through 12 Months Post Transplant — 2.03; -2.19 mL/min/1.73m^2
Phase 3 N=1,101 Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Metastatic Prostate Cancer
Primary: Investigator-assessed Radiographic Progression-free Survival (rPFS), Per Prostate Cancer Working Group 3 (PCWG3) Criteria in Phosphatase and Tensin Homolog (PTEN) Loss…
Phase 3 N=122 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate Adenocarcinoma
Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions
Phase 3 N=149 Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Parkinson's Disease
Primary: Total UPDRS I, II, III Scores — -5.97; -5.15; -1.31 units on a scale — p=0.0004
Phase 3 N=1,596 A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Primary: All-Cause Death: Time to Event — 8.3; 0.1; 8.3; 0.7 percentage of participants — p=<0.001
Phase 3 N=228 Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
Osteoporosis · Osteoporosis, Age-Related · Osteoporosis Localized to Spine
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 12 — 8.4820; 1.1654 percent change — p=<0.0001
Phase 3 N=186 A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants
Excessive Bleeding During Surgery
Primary: Percentage of Participants Achieving Hemostasis Within 4 Minutes After Treatment Start (T4) — 100.0; 100.0; 93.3; 90.9 percentage of participants — p=< 0.001
Phase 3 N=8 A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
Respiratory Syncytial Virus Infections
Primary: Number of Participants Reporting Any Serious Adverse Events (SAEs) — 0; 0; 0 Participants
Phase 3 N=19 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Myelokathexis · Infections · Neutropenia
Primary: Severity of Infection — 12.5; 9 score on a scale (with no maximum)
Phase 3 N=26 Emergency Treatment of Coral Snake Envenomation With Antivenom
Coral Snake Bite · Toxic Effect of Coral Snake Venom
Primary: Number of Participants Who Survived — 25 Participants
Phase 3 N=392 Individualizing Pharmacotherapy for African American Smokers
Smoking Cessation
Primary: Number of Participants With Biochemically Verified Smoking Abstinence at Week 12 — 23; 34 Participants
Phase 3 N=263 ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
Clostridioides Difficile Infection
Primary: Cohort 1: Recurrence of CDI and Sustained Clinical Response — 4; 25 Participants
Phase 3 N=308 Use of Dexamethasone in Pediatric Asthma Exacerbations
Asthma
Primary: Number of Participants Returning to Care Following Discharge From the Emergency Department — 14; 12 Participants
Phase 3 N=104 A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression
Prostate Cancer
Primary: Rate of Patient Recruitment to a Randomised Chemoprevention Study in Men Enrolled on an Active Surveillance Programme for Prostate Cancer. Number Accrued Per Month…